-+ 0.00%
-+ 0.00%
-+ 0.00%

Phathom Pharmaceuticals Q3 2026 net revenues climb 71% year over year to $84.7 million

PUBT·10/29/2026 11:45:23
Phathom Pharmaceuticals Q3 2026 net revenues climb 71% year over year to $84.7 million
  • Phathom Pharmaceuticals’ Q3 2026 net revenues climbed 71% year over year to $84.7 million.
  • Operating profit excluding stock-based compensation remained positive for a second consecutive quarter, while net cash generated totaled $2.1 million.
  • Covered VOQUEZNA prescriptions rose approximately 19% from Q2 2026 to approximately 248,000.
  • Reaffirmed 2026 net revenues guidance of $310 million–$325 million and non-GAAP operating expenses guidance of $235 million–$245 million.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Phathom Pharmaceuticals Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.